Compare Ares Capital Corporation (ARCC) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Boston Scientific Corporation — how do they compare? Ares Capital Corporation trades at $19.97 (market cap $14.34B), while Boston Scientific Corporation trades at $51.07 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 5.2× Ares Capital Corporation's market cap, and Ares Capital Corporation pays a 9.61% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| ARCC | BSX | |
|---|---|---|
Market Cap | $14.34B | $74.19B |
Sector | Financials | Health |
52-Week High | $22.68 | $108.14 |
52-Week Low | $17.45 | $42.63 |
Dividend Yield | 9.61% | — |
Enterprise Value | — | $86.27B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
